Pharma BD Deal Intelligence
Astellas acquired Ganymed for $1.4B for oncology.
Astellas to acquire Ganymed for EUR 422M upfront plus up to EUR 860M milestones for IMAB362.
Reports the FDA's class-first approval of Vyloy (zolbetuximab) for CLDN18.2-positive HER2-negative locally advanced/metastatic gastric and GEJ adenocarcinoma,…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Astellas Pharma acquired Ganymed Pharmaceuticals for EUR 422 million upfront plus up to EUR 860 million in milestones (up to roughly $1.4 billion total), gaining IMAB362 (claudin 18.2-targeting antibody, later zolbetuximab) and Ganymed's broader oncology antibody pipeline. The deal furthered Astellas' oncology focus and closed December 20, 2016.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Ganymed Pharmaceuticals (this deal) | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
| Astellas Pharma Inc. / OSI Pharmaceuticals | 2010 | $4.0B | 33 |
← Browse all deals · How we score deals
More: 2016 deals · Astellas Pharma Inc. deals · Oncology deals